Description
Release form
Solution for intravenous and intramuscular administration
Packing
3 ampoules of 4 ml.
Pharmacological action
Pharmacodynamics
Cereton is a nootropic drug. Central cholinostimulator, which contains 40.5% metabolically protected choline. Metabolic protection promotes the release of choline in the brain. Provides the synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system, activates the reticular formation. Increases the linear velocity of blood flow on the side, traumatic brain damage, helps to normalize the spatio-temporal characteristics: spontaneous bioelectric activity of the brain, regression of focal neurological symptoms and recovery of consciousness has a positive effect on cognitive and behavioral responses of patients with cerebrovascular diseases (discirculatory encephalopathy and residual effects of cerebrovascular accident). It has a preventive and corrective effect on pathogenetic factors of the involutional psycho-organic syndrome, changes the phospholipid composition of neuronal membranes: it participates in the synthesis of phosphatidylcholine (membrane phospholipid), improves the plasticity of neuronal membranes. Stimulates dose-dependent secretion of acetylcholine under physiological conditions, improves synaptic transmission, receptor function. It does not affect the reproductive cycle and does not have a teratogenic, mutagenic effect.
Pharmacokinetics of
Parenteral administration (10 mg / kg) Cereton predominantly accumulates in the brain, lungs and liver. Absorption – 88%, easily penetrates the blood-brain barrier (when taken orally, the concentration in the brain is 45% of that in the plasma). 85% of the preparation in the form of carbon dioxide is excreted by the lungs, the remaining amount (15%) is excreted by the kidneys and through the intestines.
Indications
Acute and recovery periods of severe head injury and ischemic stroke, recovery period of hemorrhagic stroke, occurring with focal hemispheric symptoms or symptoms of damage to the brain stem
psycho-organic syndrome against the background of degenerative and involutional changes in the brain
chronic cerebrovascular insufficiency
cognitive disorders (impaired mental function, memory, confusion, disorientation, decreased motivation, initiative and ability to concentrate) including with dementia and encephalopathy
senile pseudomelancholy.
Contraindications
hypersensitivity to the drug
acute stage hemorrhagic stroke
pregnancy breastfeeding
children under 18 years of age (due to lack of data).
Special instructions
Cereton does not affect the rate of psychomotor reactions.
Composition of
1 ml contains: active substance: glycerylphosphoryl hydrophyl dlf64 250 mg: water 250 mg Composition
1 ml contains: active substance: glycerylphosphorylcholine hydrate 250 mg,
excipients: water for injection
Dosage and administration of
In acute conditions, the solution is administered intravenously (slowly) or deeply intramuscularly at 1000 mg (1 ampoule) per day for 10-15 days.
Side effects of
Nausea may occur (mainly as a result of dopaminergic activation), in this case, reduce the dose of the drug.
Allergic reactions.
Solution for injection
From the digestive system: constipation, diarrhea, dry oral mucosa, pharyngitis.
From the nervous system: headache, drowsiness, insomnia, aggressiveness, anxiety, nervousness, cerebral ischemia, cramps, dizziness.
From the skin: rash, urticaria.
Other: pain at the injection site, increased urination.
Overdose
Nausea may occur. Treatment: symptomatic therapy.
Storage Conditions In a light-proof location, at 2-25 ° C.
Deystvuyuschee substance
choline alfoscerol
Form of Treatment
simply entails dlya inaektsiy and infusing
